XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Business Acquisition (Tables)
9 Months Ended
Sep. 30, 2021
Business Combinations [Abstract]  
Summary of Fair Value of Purchase Price Consideration

The following table summarizes the fair value of purchase price consideration to acquire Anelixis (in thousands):

 

Description

 

Amount

 

Fair value of purchase consideration:

 

 

 

 

Common shares issued (1)

 

$

1,194

 

Preferred shares issued (2)

 

 

69,723

 

Options assumed (3)

 

 

2,950

 

Warrants assumed (3)

 

 

12,944

 

Total purchase consideration

 

$

86,811

 

 

(1)

The fair value of common shares issued in the merger is based on 175,488 shares issued on the September 14, 2020 acquisition date at the closing price of the Company's common stock of $6.80 per share.

 

(2)

The fair value of preferred shares issued in the merger is based on the amount per share of Series X1 preferred stock in the September 2020 Purchase Agreement.

 

(3)

The fair value of the options and warrants assumed and replaced in the merger is based on applying the Black-Scholes valuation method using appropriate inputs of volatility rates ranging from 82% to 83%, expected terms of 5.0 to 5.9 years and risk-free rates of 0.27% to 0.45%.

Summary of Estimate of Fair Value of Assets Acquired and Liabilities Assumed

The following is an allocation of purchase price as of the September 14, 2020, acquisition closing date based upon an estimate of the fair value of the assets acquired and the liabilities assumed by the Company in the acquisition (in thousands):

 

Description

 

Amount

 

Cash and cash equivalents

 

$

11,035

 

Prepaid expenses and other current assets

 

 

26

 

Other non-current assets

 

 

11

 

Accounts payable

 

 

(580

)

Accrued expenses and other liabilities

 

 

(205

)

Deferred tax liability

 

 

(4,510

)

Net identifiable assets acquired

 

 

5,777

 

 

 

 

 

 

Goodwill

 

 

48,648

 

Identifiable intangible assets

 

 

32,386

 

Net assets acquired

 

$

86,811

 

Schedule of Unaudited Pro Forma Combined Financial Information

The following unaudited pro forma combined financial information is presented to illustrate the estimated effects of the Merger based on the historical financial statements and accounting records of Eledon and Anelixis after giving effect to the Merger and the Merger-related pro forma adjustments.

 

 

 

Three Months

Ended

September 30,

 

 

Nine Months

Ended

September 30,

 

 

 

2020

 

 

2020

 

Revenue

 

$

120

 

 

$

120

 

 

 

 

 

 

 

 

 

 

Net loss and other comprehensive loss

 

$

(5,375

)

 

$

(19,140

)